Fidelity's Parent FMR Holds 6.4% Of Tarsus Pharmaceuticals, A Passive Stake
FMR LLC reports 3,143,158.2 Tarsus shares as of September 30, weeks after the eye-drug maker raised its 2026 Xdemvy sales outlook.
FMR LLC, the parent of Fidelity, holds 6.4% of Tarsus Pharmaceuticals, or 3,143,158.2 common shares as of September 30, according to a passive ownership disclosure filed with the SEC on Thursday. Tarsus, which develops and sells eye-care therapeutics led by the Demodex blepharitis drop Xdemvy, shares the news with a record sales quarter behind it.
How Fidelity holds the shares
FMR has sole voting power over 3,139,690 of the shares and shared voting power over none. Abigail P. Johnson, FMR's chairman and CEO, is a joint reporting person and also shows 6.4%, though the filing gives her no voting power in her own name.
The exhibit lists the holding entities, among them FIAM, Fidelity Management & Research Company and Fidelity Management Trust Company. FMR certified that the shares were acquired and held in the ordinary course of business, not to change or influence control of Tarsus.
Tarsus shares traded at $68.00 in Thursday trading, down about 2% from the prior close of $69.07. The company's market value was $3.4 billion.
A record quarter for Xdemvy
Xdemvy, approved by the FDA in July 2023 and launched in the US the next month, is Tarsus's marketed product. Net sales were more than $646 million from launch through the end of 2025, according to the company's annual report.
In the third quarter, Tarsus reported record Xdemvy sales of $194.6 million, up nearly 64% from a year earlier. It raised its 2026 sales outlook to a range of $715 million to $730 million. The company still posted a net loss for the quarter and ended September with about $310 million in cash.
CEO Bobby Azamian said Tarsus has now passed $1 billion in cumulative net product sales of Xdemvy since launch.
Pipeline readouts due in 2027
The company uses the same active ingredient, lotilaner, in candidates for ocular rosacea and Lyme disease prevention. Tarsus expects top-line data from both programs in the first half of 2027.
Top-line results from the ocular rosacea and Lyme disease prevention programs are due in the first half of 2027.
Sources
- SCHEDULE 13G — FMR LLC re: TARSUS PHARMACEUTICALS INC (TARS) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — SEC EDGAR
- Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ... — Yahoo Finance
- Tarsus Pharmaceuticals Q3 Earnings Call Highlights — Yahoo Finance
- Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates — Yahoo Finance
- Tarsus Pharmaceuticals, Inc. GAAP EPS of -$14.40 misses by $10.38, revenue of $194.5M beats by $3.72M | Seeking Alpha — seekingalpha.com
- How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78% — Yahoo Finance